These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33753749)

  • 1. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific.
    Cook JH; Melloni GEM; Gulhan DC; Park PJ; Haigis KM
    Nat Commun; 2021 Mar; 12(1):1808. PubMed ID: 33753749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue-Specific Oncogenic Activity of KRAS
    Poulin EJ; Bera AK; Lu J; Lin YJ; Strasser SD; Paulo JA; Huang TQ; Morales C; Yan W; Cook J; Nowak JA; Brubaker DK; Joughin BA; Johnson CW; DeStefanis RA; Ghazi PC; Gondi S; Wales TE; Iacob RE; Bogdanova L; Gierut JJ; Li Y; Engen JR; Perez-Mancera PA; Braun BS; Gygi SP; Lauffenburger DA; Westover KD; Haigis KM
    Cancer Discov; 2019 Jun; 9(6):738-755. PubMed ID: 30952657
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of KRAS Genetic Interactions on Outcomes in Cancers of the Lung, Pancreas, and Colorectum.
    Grabski IN; Heymach JV; Kehl KL; Kopetz S; Lau KS; Riely GJ; Schrag D; Yaeger R; Irizarry RA; Haigis KM
    Cancer Epidemiol Biomarkers Prev; 2024 Jan; 33(1):158-169. PubMed ID: 37943166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS Alleles: The Devil Is in the Detail.
    Haigis KM
    Trends Cancer; 2017 Oct; 3(10):686-697. PubMed ID: 28958387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis.
    Le Roux Ö; Pershing NLK; Kaltenbrun E; Newman NJ; Everitt JI; Baldelli E; Pierobon M; Petricoin EF; Counter CM
    Elife; 2022 Sep; 11():. PubMed ID: 36069770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular epidemiology and diagnostics of KRAS mutations in human cancer.
    Timar J; Kashofer K
    Cancer Metastasis Rev; 2020 Dec; 39(4):1029-1038. PubMed ID: 32725342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective targeting of the oncogenic
    Gao Q; Ouyang W; Kang B; Han X; Xiong Y; Ding R; Li Y; Wang F; Huang L; Chen L; Wang D; Dong X; Zhang Z; Li Y; Ze B; Hou Y; Yang H; Ma Y; Gu Y; Chao CC
    Theranostics; 2020; 10(11):5137-5153. PubMed ID: 32308773
    [No Abstract]   [Full Text] [Related]  

  • 8. A Facile Method to Engineer Mutant Kras Alleles in an Isogenic Cell Background.
    Budagyan K; Chernoff J
    Methods Mol Biol; 2021; 2262():323-334. PubMed ID: 33977487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
    Haley L; Tseng LH; Zheng G; Dudley J; Anderson DA; Azad NS; Gocke CD; Eshleman JR; Lin MT
    Mod Pathol; 2015 Oct; 28(10):1390-9. PubMed ID: 26226847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.
    Parsons BL; McKim KL; Myers MB
    Environ Mol Mutagen; 2017 Aug; 58(7):466-476. PubMed ID: 28755461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An
    Zafra MP; Parsons MJ; Kim J; Alonso-Curbelo D; Goswami S; Schatoff EM; Han T; Katti A; Fernandez MTC; Wilkinson JE; Piskounova E; Dow LE
    Cancer Discov; 2020 Nov; 10(11):1654-1671. PubMed ID: 32792368
    [No Abstract]   [Full Text] [Related]  

  • 12. Oncogenic activating mutations are associated with local copy gain.
    Modrek B; Ge L; Pandita A; Lin E; Mohan S; Yue P; Guerrero S; Lin WM; Pham T; Modrusan Z; Seshagiri S; Stern HM; Waring P; Garraway LA; Chant J; Stokoe D; Cavet G
    Mol Cancer Res; 2009 Aug; 7(8):1244-52. PubMed ID: 19671679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas.
    Baldelli E; El Gazzah E; Moran JC; Hodge KA; Manojlovic Z; Bassiouni R; Carpten JD; Ludovini V; Baglivo S; Crinò L; Bianconi F; Dong T; Loffredo J; Petricoin EF; Pierobon M
    Genes (Basel); 2021 Sep; 12(9):. PubMed ID: 34573384
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessment of mutation probabilities of KRAS G12 missense mutants and their long-timescale dynamics by atomistic molecular simulations and Markov state modeling.
    Pantsar T; Rissanen S; Dauch D; Laitinen T; Vattulainen I; Poso A
    PLoS Comput Biol; 2018 Sep; 14(9):e1006458. PubMed ID: 30199525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
    Chen D; Huang X; Cai J; Guo S; Qian W; Wery JP; Li QX
    Oncotarget; 2015 Dec; 6(38):40815-21. PubMed ID: 26512781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
    Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F;
    Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS mutation allele frequency threshold alters prognosis in right-sided resected pancreatic cancer.
    Nauheim D; Moskal D; Renslo B; Chadwick M; Jiang W; Yeo CJ; Nevler A; Bowne W; Lavu H
    J Surg Oncol; 2022 Aug; 126(2):314-321. PubMed ID: 35333412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.
    Soh J; Okumura N; Lockwood WW; Yamamoto H; Shigematsu H; Zhang W; Chari R; Shames DS; Tang X; MacAulay C; Varella-Garcia M; Vooder T; Wistuba II; Lam S; Brekken R; Toyooka S; Minna JD; Lam WL; Gazdar AF
    PLoS One; 2009 Oct; 4(10):e7464. PubMed ID: 19826477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
    Kundu S; Ali MA; Handin N; Conway LP; Rendo V; Artursson P; He L; Globisch D; Sjöblom T
    J Exp Clin Cancer Res; 2021 Jul; 40(1):225. PubMed ID: 34233735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Facile Method to Append a Bio-ID Tag to Endogenous Mutant Kras Alleles.
    Budagyan K; Cannon AC; Chernoff J
    Methods Mol Biol; 2024; 2797():351-362. PubMed ID: 38570472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.